New cell combo targets tough stomach cancer
NCT ID NCT07298200
First seen Jan 04, 2026 · Last updated May 01, 2026 · Updated 17 times
Summary
This early-stage trial tests a new treatment for advanced stomach cancer that has not responded to standard therapies. It combines a vaccine made from the patient's own tumor markers (neoantigens) with immune cells trained to attack the cancer. The main goals are to see if the combination is safe and whether it can shrink tumors or help patients live longer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED GASTRIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Nanjing Drum Tower Hospital
RECRUITINGNanjing, Jiangsu, China
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.